Chinese biotech developing bispecific and other antibody cancer drugs, with a major licensing deal with Summit Therapeutics.
Chinese biotech developing bispecific and other antibody cancer drugs, with a major licensing deal with Summit Therapeutics.
Sells its approved antibody drugs inside China through hospitals, and licensed ivonescimab, its newest lead antibody, to Summit Therapeutics for the US, Europe and several other markets outside China. That brings upfront and milestone payments now and royalties on Summit's sales later, while Akeso keeps China.
In one line: A Chinese oncology biotech known for its PD-1/VEGF bispecific antibody.
Moat: narrow (IP / patents, process know-how). Proprietary bispecific-antibody platform validated by a major US licensing/royalty deal.
Headquarters: Zhongshan, China · Founded: 2012 · Employees: 3,761
Size Akeso (9926.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $7.01B, the 203rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$59.00 on 18 Nov 2026.
Performance Over six months the shares fell 47.7%, against -0.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 42.5% over the last twelve months (peer median +8.9%); the operating margin is -24.7% (peer median 13.8%).
Valuation It trades at 12.9× enterprise value to sales against a peer median of 4.3× (3rd most expensive of 19).
Capital Return on invested capital runs 24.5 points below its cost of capital (7.5% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.86B | HK$3.31B | HK$2.30B | HK$5.00B | HK$997M |
| Revenue growth | — | +44% | -54% | +402% | — |
| Gross profit | HK$2.93B | HK$2.60B | HK$1.99B | HK$4.70B | HK$765M |
| EBITDA | -HK$615M | -HK$738M | -HK$411M | HK$2.42B | -HK$1.41B |
| Net income | -HK$1.08B | -HK$1.21B | -HK$558M | HK$2.24B | -HK$1.36B |
| Free cash flow | -HK$1.39B | -HK$2.03B | -HK$1.20B | HK$1.95B | -HK$2.27B |
| Capital expenditure | HK$702M | HK$804M | HK$541M | HK$869M | HK$802M |
| Total debt | n/a | HK$5.07B | HK$4.21B | HK$3.29B | HK$2.11B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | 12.9× | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | $44.9B | -24% | +11% | 27% | 8.1× | 9.1% |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 6.3× | 19.1% |
| Summit Therapeutics SMMT | $8.40B | -41% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9926.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -35.5% | +2.2% | 2nd lowest of 21 |
| 6-month return | -47.7% | -0.4% | lowest of 20 |
| Distance from 52-week high | -62.2% | -18.1% | lowest of 21 |
| Revenue growth (TTM) | +42.5% | +8.9% | 4th highest of 18 |
| Operating margin | -24.7% | 13.8% | 3rd lowest of 19 |
| EV / Sales | 12.9× | 4.3× | 3rd most expensive of 19 |
| ROIC minus cost of capital | -24.5 pp | +1.5 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | 12.9× | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 8.6× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 5.8× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | 44.3× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | 64.3× | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 2.1× | -6.8% | +10.8% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 1.1× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 4.1× | 25.0% | +10.7% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 7.3× | 23.9% | +16.6% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 1.9× | -6.2% | +18.4% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 7.3× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 2.4× | 7.1% | +7.1% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 3.5× | -11.9% | +4.2% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 2.1× | 2.9% | +6.6% |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 5.9× | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 3.4× | 17.2% | +8.7% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 4.3× | n/a | n/a |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 4.4× | 1.1% | +303.3% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% | +7.3% |